--- title: "Xenetic Biosciences (XBIO) news: reverse split and offering" url: "https://aibio.space/companies/xenetic-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "XBIO reverse split, offering and merger news: Xenetic files investor presentation on proposed transaction with Santersus. Xenetic Biosciences, Inc." --- XBIO Xenetic Biosciences, Inc. NASDAQ · United States # Xenetic Biosciences (XBIO) news XBIO reverse split, offering and merger news Listings · 2026-09-23 ## [Xenetic files investor presentation on proposed transaction with Santersus](https://aibio.space/news/xenetic-files-investor-presentation-proposed-transaction-santersus/) The September 2026 deck's risk list includes a possible reverse stock split to meet Nasdaq listing requirements. ## Latest Xenetic Biosciences news 1. 2026-09-16 Financings [Xenetic Biosciences agrees to acquire Santersus AG in all-stock share exchange](https://aibio.space/news/xenetic-biosciences-agrees-acquire-santersus-ag-all-stock-share/) The deal needs Xenetic stockholder approval. Pro forma, current Xenetic holders would own approximately 15.0% and Santersus holders approximately 85.0%. 2. 2025-10-10 Financings [Xenetic Biosciences prices $4.5 million offering of 735,000 shares at $6.12](https://aibio.space/news/xenetic-biosciences-prices-4-5-million-offering-735-000-shares-6-12/) Canaccord Genuity is sole bookrunner. Xenetic plans to use net proceeds for working capital and general corporate purposes. ## Xenetic Biosciences at a glance - **Ticker**: XBIO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $6.5 million ### Related companies - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) NASDAQ: TARA - [Clene](https://aibio.space/companies/clene/) NASDAQ: CLNN - [Vanda Pharmaceuticals](https://aibio.space/companies/vanda-pharmaceuticals/) NASDAQ: VNDA - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT - [Vyome Holdings](https://aibio.space/companies/vyome/) NASDAQ: HIND - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) NASDAQ: HRMY - [Cerenome](https://aibio.space/companies/cerenome/) NASDAQ: CNSY - [Jaguar Health](https://aibio.space/companies/jaguar-health/) NASDAQ: JAGX ### Also on NASDAQ - [Neumora Therapeutics](https://aibio.space/companies/neumora-therapeutics/) NMRA - [Estrella Immunopharma](https://aibio.space/companies/estrella-immunopharma/) ESLA - [Edesa Biotech](https://aibio.space/companies/edesa-biotech/) EDSA - [Alumis](https://aibio.space/companies/alumis/) ALMS - [Mustang Bio](https://aibio.space/companies/mustang-bio/) MBIO - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) ACRV ## Xenetic Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | [$2.5 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | | Research and development | [$3.1 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | | Net income (loss) | [-$2.7 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | [-$4.0 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | | Cash from operations | [-$2.3 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | [-$2.8 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/) | | Cash and equivalents | [$7.9 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826006061/) | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1534525/000168316826006061/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Xenetic Biosciences Did Xenetic Biosciences do a reverse stock split? Our latest story on this, dated Sep 23, 2026: "Xenetic files investor presentation on proposed transaction with Santersus". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xenetic-files-investor-presentation-proposed-transaction-santersus/). Has Xenetic Biosciences raised money recently? Our latest story on this, dated Oct 10, 2025: "Xenetic Biosciences prices $4.5 million offering of 735,000 shares at $6.12". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xenetic-biosciences-prices-4-5-million-offering-735-000-shares-6-12/). Is Xenetic Biosciences involved in a merger or acquisition? Our latest story on this, dated Sep 16, 2026: "Xenetic Biosciences agrees to acquire Santersus AG in all-stock share exchange". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xenetic-biosciences-agrees-acquire-santersus-ag-all-stock-share/). What is the ticker symbol of Xenetic Biosciences? Xenetic Biosciences, Inc. trades under the ticker XBIO on NASDAQ. Where is Xenetic Biosciences listed? Xenetic Biosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Xenetic Biosciences? The SEC Central Index Key (CIK) for Xenetic Biosciences, Inc. is 1534525. Its filings are on SEC EDGAR. How many shares does Xenetic Biosciences have outstanding? 2,343,181 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Xenetic Biosciences listed under? Our directory records Xenetic Biosciences, Inc. under United States. What does Xenetic Biosciences do? Our directory classifies Xenetic Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Xenetic Biosciences? The ISIN recorded for Xenetic Biosciences, Inc. is US9840156023. Does aibio.space cover Xenetic Biosciences? aibio.space lists Xenetic Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Xenetic Biosciences incorporated? SEC records list its state or country of incorporation as NV. What was Xenetic Biosciences's revenue last year? $3.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Xenetic Biosciences profitable? Xenetic Biosciences, Inc. reported a net loss of $2.7 million for the fiscal year ended Dec 31, 2025, and used $2.3 million of cash in operations, per its annual report to the SEC. How much does Xenetic Biosciences spend on research and development? $3.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Xenetic Biosciences Members talk about Xenetic Biosciences (XBIO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Xenetic Biosciences, newest first. Each line links the filing it comes from. 1. 2026-09-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/xenetic_ex9901.htm) 2. 2026-09-16 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/xenetic_ex9901.htm) 3. 2025-10-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1534525/000168316825007488/xenetic_424b5.htm) 4. 2025-04-10 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534525/000168316825002396/xenetic_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:XBIO on TradingView](https://www.tradingview.com/symbols/NASDAQ-XBIO/). ## SEC filings and registration - **SEC name**: Xenetic Biosciences, Inc. - **CIK**: 1534525 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: XBIO (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 945 CONCORD ST., FRAMINGHAM, MA, 01701 - **Phone**: 781-778-7720 - **Shares outstanding**: 2,343,181 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: General Sales & Leasing, Inc.; GENERAL AIRCRAFT INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/xenetic_8k.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/xenetic_8k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/xenetic_8k.htm) filed 2026-08-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1534525/000168316826006061/xenetic_i10q-063026.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/xenetic_8k.htm) filed 2026-05-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1534525/000168316826003727/xenetic_i10q-033126.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1534525/000168316826003203/xenetic_8k.htm) filed 2026-04-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/xenetic_8k.htm) filed 2026-03-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001534525), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Xenetic Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker XBIO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Xenetic Biosciences, Inc. - **Ticker**: XBIO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US9840156023 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-XBIO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/xenetic-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Xenetic Biosciences (XBIO) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/xenetic-biosciences/